hombre ... si ya lo que se pone encima del tapete son los bemoles ( liderazgo )de Trump ... pues joer ... no se supone que el congreso esta bajo control republicano? .... en fin ...
Los futuros van mejorando ... ahora planos ... edito: ya no tan planos
ya veremos si vemos hoy al gato o que ...
Achillion Pharma (ACHN) Granted USPTO Matter Patent for Small Molecule Complement Alternative Pathway Factor D Inhibitors
Ahora mismo +18% en pre market (no he visto con que volumen)
A ver si Alexion hace una oferta!
De momento 100 cromazos...
ACHN
Y la caída general de ayer básicamente es el trumpazo de vuelta a la realidad tras la euforia porque Trump no plasma sus promesas, y de la reforma impositiva ya ha dicho que hasta pasado agosto nada, con lo que el mercado descuenta sus efectos hasta el año que viene.
«Después de nada, o después de todo/ supe que todo no era más que nada.»
IDRA
+20% en pre por upgrade de PO a 8$ de JMP y resultados que superan expectativas
Tiene pinta de corto. ¿Alguien la lleva fresca?
«Después de nada, o después de todo/ supe que todo no era más que nada.»
DUBLIN, Ireland, March 22, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced the presentation of new data on the use of RAVICTI® (glycerol phenylbutyrate) Oral Liquid in children living with urea cycle disorders (UCD) two months to two years of age. These data will be presented on Thursday, March 23 at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting in Phoenix, Arizona.
The study results are from two clinical trials that enrolled children with UCDs aged two months to less than two years. Study participants were predominantly on relatively stable doses of sodium phenylbutyrate and switched to equivalent doses of RAVICTI. The primary outcomes measured in the study were targeted mean normalized plasma ammonia of less than 100 μmol/L, hyperammonemic crises (HACs) and adverse events (AEs). Safety and efficacy was also evaluated after patients transitioned to RAVICTI.
"The RAVICTI development program is part of our overall approach to reinvest in our medicines for people living with rare diseases," said Jeffrey W. Sherman, M.D., FACP, executive vice president, research and development and chief medical officer, Horizon Pharma plc. "While UCDs are very rare and can be devastating, continued advancements in diagnosis and ongoing studies evaluating management options are helping improve the long-term outcome of people living with the disorder."
RAVICTI is currently indicated for use as a nitrogen-binding agent for chronic management of adult and pediatric patients two years of age or greater with UCDs who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. RAVICTI is not indicated for patients less than two years of age. In June 2016, Horizon submitted a supplemental New Drug Applications (sNDA) with the U.S. Food and Drug Administration (FDA) seeking to expand the approved age range for RAVICTI to include children as young as two months of age.
The poster presentation (abstract #2873; poster #71), entitled "Safety and Efficacy of Glycerol Phenylbutyrate for Management of Urea Cycle Disorders in Patients Aged 2 Months to 2 Years," will be presented on Thursday, March 23, 2017 from 10:00 a.m. - 11:30 a.m. at the ACMG Annual Meeting.
pero pobre hombre, como os metéis con él... Si acaba de decir que lo está dando todo, que no para de currar!
Si el viernes no es aprobado el Trumpcare se enviará una peligrosa señal acerca de la reforma fiscal, el gasto de infraestructuras y la desregulación. Es decir, fallarían los tres motores de lo que se ha denominado por los medios de comunicación como “Trump rally”.
